--- title: "Nasus Pharma (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman Purchases 2,900 Shares" type: "News" locale: "en" url: "https://longbridge.com/en/news/283982372.md" description: "Nasus Pharma CEO Dan Benjamin Teleman purchased 2,900 shares of the company's stock at an average price of $3.76 per share, totaling $10,904. This acquisition increased his ownership to 156,991 shares, valued at $590,286.16, reflecting a 1.88% increase. The transaction was disclosed in an SEC filing. Currently, Nasus Pharma's stock is trading at $3.40, down 12.6%, with a 52-week range of $1.98 to $9.99. Analysts have a consensus \"Buy\" rating with a target price of $18.00." datetime: "2026-04-24T10:34:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283982372.md) - [en](https://longbridge.com/en/news/283982372.md) - [zh-HK](https://longbridge.com/zh-HK/news/283982372.md) generator: "portal-rs" --- # Nasus Pharma (NYSEAMERICAN:NSRX) CEO Dan Benjamin Teleman Purchases 2,900 Shares Nasus Pharma Ltd. (NYSEAMERICAN:NSRX - Get Free Report) CEO Dan Benjamin Teleman bought 2,900 shares of the firm's stock in a transaction dated Wednesday, April 22nd. The shares were acquired at an average cost of $3.76 per share, with a total value of $10,904.00. Following the completion of the transaction, the chief executive officer owned 156,991 shares of the company's stock, valued at $590,286.16. This represents a 1.88% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. ## Nasus Pharma Trading Down 12.6% Shares of NYSEAMERICAN NSRX opened at $3.40 on Friday. Nasus Pharma Ltd. has a fifty-two week low of $1.98 and a fifty-two week high of $9.99. The company has a 50-day simple moving average of $3.60. ## Analyst Upgrades and Downgrades Separately, Citizens Jmp dropped their target price on Nasus Pharma from $19.00 to $18.00 and set a "market outperform" rating on the stock in a report on Thursday, March 26th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Nasus Pharma presently has a consensus rating of "Buy" and an average target price of $18.00. **Read Our Latest Stock Report on NSRX** ## About Nasus Pharma (Get Free Report) Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions. Nasus Pharma Ltd. is based in TEL AVIV, Israel. ## Read More - Five stocks we like better than Nasus Pharma *This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\].* Insider Buying or Selling at Nasus Pharma? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Nasus Pharma and related companies. From Our Partners Your book is inside The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ... Profits Run Why BlackRock is buying this "Penny Stock" Recent 13F filings show institutional giants like BlackRock and Morgan Stanley quietly accumulating shares in ... Behind the Markets The SpaceX story everyone missed While the world watched NASA's Artemis mission, Elon Musk's team quietly launched its own rocket — a move Jeff... Brownstone Research My feud with Zohran Mamdani Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac... Stansberry Research Your name isn't on our protected list yet I checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern... American Alternative Read this or regret it forever Porter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the bigg... Porter & Company Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top... InvestorPlace Trade this between 9:30 and 10:45 am EST The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ... Base Camp Trading ### Related Stocks - [NSRX.US](https://longbridge.com/en/quote/NSRX.US.md) - [CFG.US](https://longbridge.com/en/quote/CFG.US.md) - [BLK.US](https://longbridge.com/en/quote/BLK.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [DXYZ.US](https://longbridge.com/en/quote/DXYZ.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [TW.US](https://longbridge.com/en/quote/TW.US.md) - [MKTW.US](https://longbridge.com/en/quote/MKTW.US.md) - [SCOR.US](https://longbridge.com/en/quote/SCOR.US.md) - [NA.US](https://longbridge.com/en/quote/NA.US.md) - [INTR.US](https://longbridge.com/en/quote/INTR.US.md) - [NSIT.US](https://longbridge.com/en/quote/NSIT.US.md) - [RUN.US](https://longbridge.com/en/quote/RUN.US.md) - [GPRO.US](https://longbridge.com/en/quote/GPRO.US.md) - [SFM.US](https://longbridge.com/en/quote/SFM.US.md) - [FMKT.US](https://longbridge.com/en/quote/FMKT.US.md) - [BNL.US](https://longbridge.com/en/quote/BNL.US.md) - [BAMV.US](https://longbridge.com/en/quote/BAMV.US.md) - [BX.US](https://longbridge.com/en/quote/BX.US.md) - [REFR.US](https://longbridge.com/en/quote/REFR.US.md) - [RSSS.US](https://longbridge.com/en/quote/RSSS.US.md) - [MJ.US](https://longbridge.com/en/quote/MJ.US.md) - [AAUM.US](https://longbridge.com/en/quote/AAUM.US.md) - [AEXA.US](https://longbridge.com/en/quote/AEXA.US.md) - [ULNV.US](https://longbridge.com/en/quote/ULNV.US.md) - [6794.JP](https://longbridge.com/en/quote/6794.JP.md) - [5017.JP](https://longbridge.com/en/quote/5017.JP.md) - [ISTR.US](https://longbridge.com/en/quote/ISTR.US.md) - [INES.AU](https://longbridge.com/en/quote/INES.AU.md) - [8963.JP](https://longbridge.com/en/quote/8963.JP.md) - [4477.JP](https://longbridge.com/en/quote/4477.JP.md) - [BASE.US](https://longbridge.com/en/quote/BASE.US.md) - [CAMP.US](https://longbridge.com/en/quote/CAMP.US.md) - [CFG-I.US](https://longbridge.com/en/quote/CFG-I.US.md) - [CFG-E.US](https://longbridge.com/en/quote/CFG-E.US.md) - [CFG-H.US](https://longbridge.com/en/quote/CFG-H.US.md) - [BTX.US](https://longbridge.com/en/quote/BTX.US.md) - [BIT.RT*.US](https://longbridge.com/en/quote/BIT.RT*.US.md) - [BDJ.US](https://longbridge.com/en/quote/BDJ.US.md) - [BSTZ.US](https://longbridge.com/en/quote/BSTZ.US.md) - [BIT.RT.US](https://longbridge.com/en/quote/BIT.RT.US.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [Nasus Pharma CEO Dan Benjamin Teleman acquires 6,550 shares for $20,305](https://longbridge.com/en/news/290425988.md) - [Innocan Pharma reports Q2 results](https://longbridge.com/en/news/297557245.md) - [Regenerex Pharma delays SEC quarterly filings amid added accounting and reconciliation work](https://longbridge.com/en/news/297685504.md) - [Vidac Pharma publishes 2025 annual report and financial statements](https://longbridge.com/en/news/297478862.md) - [LSL Pharma Group Inc. reports Q2 results](https://longbridge.com/en/news/296953883.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**